Monocrotaline Suppresses RANKL-Induced Osteoclastogenesis < b > < i > In Vitro < /i > < /b > and Prevents LPS-Induced Bone Loss < b > < i > In Vivo < /i > < /b >

Conclusion: Taken together our data demonstrate that Mon may be a potential prophylactic anti-osteoclastic agent for the treatment of osteolytic diseases caused by excessive osteoclast formation and function.Cell Physiol Biochem 2018;48:644 –656
Source: Cellular Physiology and Biochemistry - Category: Cytology Source Type: research